Finanzen von Synergy CHC Corp (SNYR)SNYRSynergy CHC Corp

Synergy CHC Corp (SNYR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nutraceuticals, accounting for 87.8% of total sales, equivalent to $4.82M. Another important revenue stream is Beverages. Understanding this composition is critical for investors evaluating how SNYR navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Synergy CHC Corp maintains a gross margin of 71.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.32%, while the net margin is -46.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SNYR converts its operational activities into shareholder value.

In the context of the broader market, SNYR competes directly with industry leaders such as SCNI and ATPC. With a market capitalization of $1.54M, it holds a significant position in the sector. When comparing efficiency, SNYR's gross margin of 71.69% stands against SCNI's -228.63% and ATPC's 85.96%. Such benchmarking helps identify whether Synergy CHC Corp is trading at a premium or discount relative to its financial performance.

The company's total revenue for Q1 2026 was only $5.49 million, down approximately 32.77% year-over-year, reflecting severe pressure on sales. The gross margin has also dropped to 36.6% in Q4 2025 from 63.3% the previous year, indicating challenges in maintaining profitability.